Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I

Page View:

On June 12, 2023, MindRank, which focuses on the use of AI to drive the development of new drugs, announced that the phase I clinical trial of its self-developed GLP-1RA small molecule oral drug MDR-001 successfully completed the first subject administration.  MDR-001 is for the treatment of indications such as obesity and type 2 diabetes.

Shanghai Medicilon Inc. (Medicilon), as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development.

Medicilon GLP-1 New Drug R&D Services 

One-stop support for new drug development and innovation

From "powerful" hypoglycemic drugs to "miracle" weight-loss drugs, the huge market space of GLP-1 is attracting more attention.  As a one-stop biopharmaceutical preclinical research and development service platform, Medicilon has already established a presence in the GLP-1 field, and can provide clients with GLP-1 drug discovery, GLP-1 pharmaceutical research (API process development & preparation), GLP-1 pharmacodynamic research, GLP-1 pharmacokinetic evaluation and GLP-1 safety evaluation.

As of the end of May 2023, Medicilon has successfully assisted 7 GLP-1 drugs to be approved for clinical trials, of which 3 GLP-1 drugs were approved by NMPA/FDA at the same time.  There was also another GLP-1 drug was approved by the US FDA, China NMPA and Australia TGA.  In addition, there are multiple GLP-1 projects are ongoing under schedule.  Relying on rich R&D experience and successful cases, Medicilon has won the trust and affirmation of the clients again and again.

Medicilon congratulates the GLP-1RA small molecule oral drug of MindRank successfully completed the administration of the first subject in clinical phase I.  It is hoped that in the next clinical practice, GLP-1RA can send good news to both diabetic and obese patients.  Medicilon will also actively embrace new technologies to speed up the new drug development process.

Relevant newsRelevant news